Global HIV and HBV Therapeutics Market Expected to Grow at a CAGR of 6.5% by 2032: Visiongain Reports Ltd


Visiongain Ltd Reports

Visiongain has released a new report titled Global HIV and HBV Therapeutics Market. It includes market segment by drug class (combination therapies, nucleoside and non-nucleoside RTIs, integrase inhibitors, protease inhibitors and others), market segment by distribution channel (hospital pharmacies, retail pharmacies and drugstores in line), as well as the impact of COVID-19 Analysis and analysis of recovery patterns (“V-shaped”, “W-shaped”, “U-shaped”, “L-shaped”), profiles of the main companies, region and country.

The global HIV and HBV therapeutics market is estimated to be worth US$36.2 billion in 2022 and is expected to grow at a CAGR of 6.5% during the forecast period 2022-2032.

Increase investment in Research and Development activities

Pharmaceutical companies focus on developing new drugs because their price can be high and life changing for the patient. Thus, the development of new therapies against HIV and HBV offers patients the possibility of receiving new treatments. The increasing attention given to therapies for these diseases by scientists and the Food and Drug Administration (FDA) has led to a drastic increase in the number of treatment choices for these patients. For example, HIV prevention research is primarily funded by a small number of large investors. The US public sector contributed 79% ($857 million) of overall global funding, while the Bill & Melinda Gates Foundation led with 95% ($121 million) of all philanthropic sector investment in 2020.

Download an exclusive sample report

How Has COVID-19 Significantly Negatively Impacted the HIV and HBV Therapeutics Market?

The outbreak of the SARS-CoV-2 pandemic prompted organizations to contribute their resources for the development of an effective vaccine. A large number of scientists, technicians and data managers have engaged in the fight against the virus situation alongside virus-focused research and academic institutions. As a result, clinical development and research for other diseases such as HIV and HBV have been suspended and researchers have lost progress in the fight against HIV. However, little by little funding is coming back on track and slowly R&D is expected to plan for incremental growth.

How will this report help you?

Visiongain’s 353-page report provides 137 tables and 225 graphs. Our new study is suitable for anyone requiring in-depth business analyzes of the global HIV and HBV Therapeutics market along with detailed analysis of market segments. Our new study will help you assess the global and regional overall HIV and HBV Therapeutics market. Obtain financial analysis of the overall market and different segments including drug class, distribution channel and company size and capture higher market share. We believe there are strong opportunities in this growing market for HIV and HBV therapies. Find out how to use the existing and upcoming opportunities in this market to generate revenue in the near future. Moreover, the report will help you improve your strategic decision-making, enabling you to set growth strategies, strengthen analysis of other market players and maximize business productivity.

What are the current market drivers?

Growth in HIV and HBV prevalence

The major driver propelling the HIV and HBV therapeutics market is increasing prevalence of infectious diseases globally. An estimated 37.7 million people are living with HIV and around 680,000 people died of HIV-related causes in 2020. There is no cure for HIV virus infection. However, with the increasing availability of effective HIV prevention, diagnosis and treatment, the amount of care available to people and the management of these chronic diseases has enabled people with HIV infection to live a healthy life. An increase in the incidence of HIV and HBV is contributing to the high demand for therapies and creating business opportunities for pharmaceutical manufacturers.

Growing government support

Increasing government support in the form of funding is expected to drive the growth of this market. U.S. government investment, such as the CDC’s National HIV Prevention Program funding of US$928 million in fiscal year 2020, increased to US$986 million in fiscal year 2022 ; NIH – Funding for AIDS research was US$3,076 million, which increased to US$3,194 million in fiscal year 2022, which will drive R&D activities and new approvals and resulting launches.

Download an exclusive sample report

Where are the market opportunities?

Demand from emerging countries

Growing development in emerging countries in supply routes and infrastructure for pharmaceutical drugs will help boost the global market for HIV and HBV therapies. The very population of emerging economies such as China and India, coupled with increasing cases of infectious diseases, will drive high demand for HIV and HBV therapies in these countries. Also, the increase in the purchasing power of these developing economies will increase the demand for advanced healthcare and standard of living which will further contribute to the expansion of the market.

Competitive landscape

Major players operating in the HIV and HBV therapeutics market include Pfizer, Merck, GSK, AbbVie, Boehringer Ingelheim, Gilead Sciences, Janssen Pharmaceutical, Teva, BMS, and Arbustus Biopharma. These major players operating in this market have adopted various strategies including mergers and acquisitions, R&D investments, collaborations, partnerships, regional business expansion and new product launches.


  • In March 2022, ViiV Healthcare received US FDA approval for a dispersible tablet formulation of the fixed-dose combination of abacavir, dolutegravir and lamivudine. This is used for the treatment of pediatric patients weighing 10 kg to

  • In March 2022, Gilead Sciences, Inc., awarded $24 million to help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities affected by the HIV epidemic and the COVID-19 pandemic. This will contribute to increased uptake and awareness of HIV treatments

To access the data contained in this document, please send an e-mail [email protected]

Avoid missing out by staying informed – order our report now.

To find more Visiongain research reports on the Pharmacy sector, click on the following links:

Do you have any custom requirements that we can help you with? Do you need specific information about a specific country, geographic region, market segment or company? Contact us today, we can discuss your needs and see how we can help you: [email protected]

About Visiongain

Visiongain is one of the fastest growing and most innovative independent market intelligence providers, the company publishes hundreds of market research reports which he adds to his vast portfolio every year. These reports offer in-depth analysis of 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with many synergies. These markets include automotive, aviation, chemical, cybersecurity, defense, energy, food and beverage, materials, packaging, pharmacy and utilities. Our customized and syndicated market research reports offer tailored market intelligence tailored to your unique business needs.


Olivier Davison
PR at Visiongain Reports Limited
Tel: + 44 0207 336 6100
E-mail: [email protected]
The Web:

Source link